June 2, 2023
Argenica (ASX:AGN) backed in for Phase 2
Phase 1 successfully trialled a treatment for ischaemic stroke patients and Argenica is taking the next step on its roadmap to development.
Phase 1 successfully trialled a treatment for ischaemic stroke patients and Argenica is taking the next step on its roadmap to development.
Software platform powers retail giants HealthyLife intitiative
Cleanspace Holdings strike another major deal into the world’s largest healthcare market.
Arovella Therapeutics and Imugen (ASX:IMU) show combined strength in the fight against cancer.
Imricor brings its pioneering heart flutter treatment to the world with GE HealthCare.
Firebrick Pharma research has indicated the efficacy of its nasal spray in treating symptoms associated with the common cold.